Technical Analysis for CORI - Corium International, Inc.

Grade Last Price % Change Price Change
grade B 11.15 0.00% 0.00
CORI closed unchanged on Tuesday, December 12, 2017, on approximately normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical CORI trend table...

Date Alert Name Type % Chg
Dec 12 Inside Day Range Contraction 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 11 Outside Day Range Expansion 0.00%
Dec 11 Wide Bands Range Expansion 0.00%
Dec 8 Narrow Range Bar Range Contraction -0.62%
Dec 8 Wide Bands Range Expansion -0.62%
Dec 8 Gapped Up Strength -0.62%
Dec 8 Up 3 Days in a Row Strength -0.62%
Dec 7 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.36%
Dec 7 Narrow Range Bar Range Contraction 1.36%

Older signals for CORI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Corium International, Inc., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of specialty pharmaceutical products. Its products include Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for management of chronic pain, including cancer-related pain; Crest Whitestrips, a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company is also developing AG200-15, a combination hormonal contraceptive patch in Phase III clinical trials that delivers ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system, which has completed Phase I clinical trials for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed Phase I clinical trials for the treatment of benign prostatic hyperplasia. In addition, its products that have completed development, scale-up, and clinical activities include motion sickness patch for the prevention of nausea and vomiting associated with motion sickness; and urology patch for treatment of a urologic condition. Further, the company is developing Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company, Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc., and Agile Therapeutics, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Is CORI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.32
52 Week Low 2.67
Average Volume 156,302
200-Day Moving Average 7.798
50-Day Moving Average 10.6692
20-Day Moving Average 11.178
10-Day Moving Average 11.167
Average True Range 0.7034
ADX 16.38
+DI 16.55
-DI 19.49
Chandelier Exit (Long, 3 ATRs ) 10.2098
Chandelier Exit (Short, 3 ATRs ) 11.9302
Upper Bollinger Band 12.1529
Lower Bollinger Band 10.2031
Percent B (%b) 0.49
BandWidth 17.443192
MACD Line 0.1495
MACD Signal Line 0.2144
MACD Histogram -0.0649
Fundamentals Value
Market Cap 398.52 Million
Num Shares 35.7 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -6.48
Price-to-Sales 10.96
Price-to-Book 12.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.89
Resistance 3 (R3) 11.86 11.58 11.76
Resistance 2 (R2) 11.58 11.40 11.60 11.72
Resistance 1 (R1) 11.37 11.28 11.23 11.40 11.68
Pivot Point 11.09 11.09 11.03 11.11 11.09
Support 1 (S1) 10.88 10.91 10.74 10.91 10.62
Support 2 (S2) 10.60 10.79 10.62 10.58
Support 3 (S3) 10.39 10.60 10.54
Support 4 (S4) 10.42